Key Updates
01 October
2025
TAIPEI, Taiwan — Holy Young Biomedical Co., Ltd. (“Holy Young”) announced that it entered into an exclusive distribution agreement for Taiwan with renowned Japanese pharmaceutical company Kenei Pharmaceutical Co., Ltd. (“Kenei”) on October 1, 2025.
Under the agreement, Holy Young has secured exclusive distribution rights for Kenei’s product portfolio in the Taiwan market and will be responsible for product introduction, regulatory registration, marketing, channel development, and brand management.
Through this strategic partnership, the two companies aim to bring Kenei’s high-quality Japanese healthcare and pharmaceutical products to consumers in Taiwan.
Nearly 80 Years of Pharmaceutical Expertise in Japan
Founded in 1946 and headquartered in Osaka, Japan, Kenei is a well-established pharmaceutical company specializing in disinfectant products and pharmacopoeial medicines.
Since its establishment, the company has remained committed to pharmaceutical excellence through continuous product development and quality enhancement, earning the trust of healthcare institutions, pharmacies, and households throughout Japan.
Kenei has established a strong presence in Japan’s disinfectant and pharmaceutical markets, with its ethanol-based disinfectant products widely used across medical institutions, pharmacies, and households.
The company also has an extensive product portfolio spanning pharmacopoeial medicines, glycerin enemas, magnesium oxide laxatives, throat-care products, and skincare products, demonstrating its longstanding expertise across both professional healthcare and consumer health categories.
Well-Known Products Trusted by Japanese Consumers
Kenei offers a broad range of products that have gained strong recognition among Japanese consumers, including:
- Tepika Gel Hand Disinfectant Series: a widely recognized hand hygiene and disinfection brand in Japan, designed to support convenient everyday hand sanitation.
- Baby Vaseline Series: a high-purity petroleum jelly skincare range developed for babies, young children, and individuals with sensitive or delicate skin.
- Magnesium Oxide E Laxative Series: a magnesium oxide-based constipation treatment widely used in Japan and known for its gentle mechanism of action and low likelihood of dependence.
- KabaKun (カバくん) Series: A throat-care and oral-care product line featuring the friendly and recognizable “KabaKun” hippopotamus character. The series includes products designed for children and families, reflecting Kenei Pharmaceutical’s ability to combine pharmaceutical expertise with accessible everyday healthcare solutions.
- Healmild (ヒルマイルド) / / Lu Mild（ルマイルド）Moisturizing Skincare Series: A skincare range developed to provide targeted moisturizing care for dry skin.
A Strategic Milestone for Holy Young
Securing the exclusive distribution rights for Kenei marks an important milestone in Holy Young's continued business development.
The partnership brings together Kenei’s nearly 80 years of pharmaceutical manufacturing expertise, product development capabilities, and established brand presence in Japan with Holy Young’s local market knowledge, marketing and distribution resources, regulatory capabilities, and customer service network in Taiwan.
Through this collaboration, the two companies will work together to expand access to high-quality Japanese healthcare and pharmaceutical products and further develop Kenei’s presence in the Taiwan market.
Photo Caption
Left: CEO, Holy Young Biomedical Co., Ltd., Yang Ching-Hua
Right: President, Kenei Pharmaceutical Co., Ltd., Rokuro Takino
Photographed at Kenei Pharmaceutical’s headquarters in Osaka, Japan.
